Inhaled Medicines for Targeting Non-Small Cell Lung Cancer

    December 2023 in “ Pharmaceutics ”
    Arwa Omar Al Khatib, Mohamed El‐Tanani, Hisham Al-Obaidi
    TLDR Inhaling medicine may reduce side effects and improve treatment for a major lung cancer type.
    The review "Inhaled Medicines for Targeting Non-Small Cell Lung Cancer" explores the advancements in inhaled drug delivery systems for treating NSCLC, emphasizing their potential to enhance drug concentration at the tumor site while minimizing systemic side effects. It discusses various strategies, including nanoparticles, liposomes, and dry powder inhalers, which have shown improved cytotoxicity, bioavailability, and therapeutic efficacy in preclinical and clinical studies. The review underscores the importance of optimizing these delivery systems to improve patient outcomes and highlights the promise of inhaled therapies as a targeted treatment for NSCLC.
    Discuss this study in the Community →